CCCC Share Price | C4 Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is C4 Therapeutics, Inc.?

Market Cap: As of Jun 18, C4 Therapeutics, Inc. has a market capitalization of 105.80 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters ending in March 2025, C4 Therapeutics, Inc. reported net sales of 39.79 million. However, the company experienced a net profit loss of 103.28 million during the same period.Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds amounted to 215.99 million, while total assets were reported at 349.60 million.

Q: What does C4 Therapeutics, Inc. do?

Overview: C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic candidates that target and destroy disease-causing proteins, primarily in the cancer and neurodegenerative disease sectors, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025) Market-cap: USD 105.80 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.07 Return on Equity: -52.92% Price to Book: 0.54Contact Details: Address: 490 Arsenal Way, Suite 200, WATERTOWN MA: 02472 Tel: 1 617 2310700 Fax: 1 302 6555049 Website: http://www.c4thera.com/

Q: Should I buy, sell or hold C4 Therapeutics, Inc.?

Based on the current situation of C4 Therapeutics, Inc., it would be prudent to consider holding your position in the stock. The company has shown poor long-term growth, with net sales increasing at an annual rate of only 4.15% and operating profit declining significantly at -25.91% over the past five years. However, there are some positive indicators in the recent results. For instance, net sales for the half-year have grown impressively by 97.06%, although the net profit remains negative at -$60.89 million. The highest operating cash flow recorded at -$80.31 million is also noteworthy, but the negative EBITDA suggests that the company is still facing significant challenges.Additionally, the increase in promoter confidence, with a 3.45% rise in their stake, indicates a belief in the company's potential for future growth. This could be a positive sign for investors.Given these mixed signals—strong recent sales growth but ongoing profitability issues and risks—holding your investment may be the best strategy for now while monitoring the company's performance closely.

Q: Is C4 Therapeutics, Inc. technically bullish or bearish?

As of 2 June 2025, the technical trend for C4 Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. While the MACD on both weekly and monthly time frames is mildly bullish, the KST monthly indicator is bearish, suggesting mixed signals. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the indicators reflect a weak bearish sentiment with some bullish signs on longer time frames, but the prevailing trend remains mildly bearish.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.31 M

Shareholding (Dec 2025)

FII

11.38%

Held by 63 FIIs

DII

61.54%

Held by 27 DIIs

Promoter

10.19%

How big is C4 Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, C4 Therapeutics, Inc. has a market capitalization of 105.80 million and reported net sales of 39.79 million with a net profit loss of 103.28 million for the latest four quarters ending in March 2025.

View full answer

What does C4 Therapeutics, Inc. do?

22-Jun-2025

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that target and eliminate disease-causing proteins, primarily in cancer and neurodegenerative diseases. As of March 2025, it has a market cap of $105.80 million, with net sales of $7 million and a net loss of $26 million.

View full answer

Should I buy, sell or hold C4 Therapeutics, Inc.?

22-Jun-2025

Who are in the management team of C4 Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of C4 Therapeutics, Inc. includes Executive Chairman and Co-Founder Marc Cohen, President and CEO Andrew Hirsch, and Co-Founder and Director Ken Anderson.

View full answer

Is C4 Therapeutics, Inc. technically bullish or bearish?

25-Jun-2025

As of June 2, 2025, C4 Therapeutics, Inc. is in a mildly bearish trend, indicated by daily moving averages and weekly Bollinger Bands, despite some mixed signals from the MACD and KST indicators.

View full answer

Compare C4 Therapeutics, Inc. with Similar Stocks

Compugen Ltd.Carmell Corp.Spruce Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -1.90% and Operating profit at -177.92% over the last 5 years

Flat results in Sep 25

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 266 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.20

Return on Equity

-70.17%

Price to Book

1.73

Revenue and Profits:

Net Sales:

11 Million

(Quarterly Results - Dec 2025)

Net Profit:

-20 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

34.33%

6 Months

-18.67%

1 Year

29.81%

2 Years

-67.03%

3 Years

-31.3%

4 Years

-88.86%

5 Years

-93.25%

C4 Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.90%

EBIT Growth (5y)

-177.92%

EBIT to Interest (avg)

-76.95

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.07

Sales to Capital Employed (avg)

0.13

Tax Ratio

0.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

99.43%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.73

EV to EBIT

-0.68

EV to EBITDA

-0.73

EV to Capital Employed

-2.58

EV to Sales

2.68

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-70.17%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 36 Schemes (16.89%)

Foreign Institutions

Held by 63 Foreign Institutions (11.38%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -1.79% vs 72.31% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 36.34% vs -23.85% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.00",
          "val2": "11.20",
          "chgp": "-1.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.30",
          "val2": "-21.60",
          "chgp": "1.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-10.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.50",
          "val2": "-32.20",
          "chgp": "36.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,101.00%",
          "val2": "-2,108.50%",
          "chgp": "0.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.84% vs 71.15% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.28% vs 20.53% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.90",
          "val2": "35.60",
          "chgp": "0.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-96.50",
          "val2": "-109.30",
          "chgp": "11.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.70",
          "val2": "-2.40",
          "chgp": "-345.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-105.00",
          "val2": "-105.30",
          "chgp": "0.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,906.80%",
          "val2": "-3,293.00%",
          "chgp": "38.62%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

11.00

11.20

-1.79%

Operating Profit (PBDIT) excl Other Income

-21.30

-21.60

1.39%

Interest

0.00

Exceptional Items

0.00

-10.70

100.00%

Consolidate Net Profit

-20.50

-32.20

36.34%

Operating Profit Margin (Excl OI)

-2,101.00%

-2,108.50%

0.75%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -1.79% vs 72.31% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 36.34% vs -23.85% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

35.90

35.60

0.84%

Operating Profit (PBDIT) excl Other Income

-96.50

-109.30

11.71%

Interest

0.00

Exceptional Items

-10.70

-2.40

-345.83%

Consolidate Net Profit

-105.00

-105.30

0.28%

Operating Profit Margin (Excl OI)

-2,906.80%

-3,293.00%

38.62%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.84% vs 71.15% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 0.28% vs 20.53% in Dec 2024

All Annual Results

Company CV

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

Pharmaceuticals & Biotechnology

C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

Company Coordinates

Company Details

490 Arsenal Way, Suite 200 , WATERTOWN MA : 02472

Tel: 1 617 2310700

http://www.c4thera.com/

Registrar Details